Review the Immunosuppressive therapy (IST) use in eculizumab-treated patients with generalized myasthenia gravis (gMG) during the REGAIN open-label extension study
Review of the Real-World effectiveness of eculizumab in generalized myasthenia gravis (gMG) in other countries
Provide a Canadian perspective on the use of complement inhibition through Real-World cases
Review burden of disease, including symptoms, quality of life impact, functional activities, myasthenic exacerbations and crises, hospitalizations, and psychiatric burden
This program was developed by the CNSF and Alexion and was planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.
*Ticket Required for the Industry Sponsored sessions
Learning Objectives:
Recognize the clinical improvements with eculizumab were maintained by patients in all groups, including those who decreased and/or stopped concomitant Immunosuppressive therapy (IST)
Better understand the role of complement inhibition in the treatment of generalized myasthenia gravis (gMG) through recent Real-World Evidence together with a Canadian case report publication
Appreciate the burden of disease that generalized myasthenia gravis (gMG) have on patients, including the impact on their daily living
Presentations:
12:00 PM – 12:05 PM EST
Welcome and opening remarks
Faculty: Hans Katzberg
12:05 PM – 12:20 PM EST
gMG disease burden
Faculty: Hans Katzberg
12:20 PM – 12:35 PM EST
Real-world effectiveness of eculizumab
Faculty: Dubravka Dodig
12:35 PM – 12:50 PM EST
Canadian gMG case series publication
Faculty: Dubravka Dodig
12:50 PM – 1:00 PM EST
Concomitant IST use in eculizumab treated gMG patients
.png)